Drugs & Aging

, Volume 26, Issue 6, pp 483–492 | Cite as

Use of Antipsychotics among Elderly Nursing Home Residents with Dementia in the US

An Analysis of National Survey Data
  • Pravin Kamble
  • Hua Chen
  • Jeffrey T. Sherer
  • Rajender R. Aparasu
Original Research Article



Atypical antipsychotic agents are increasingly being used for the treatment of behavioural and psychological symptoms of dementia. However, recent data suggest that the risk of adverse effects may offset the benefits of atypical agents in patients with dementia.


To examine utilization of antipsychotic medications and the factors associated with use of atypical antipsychotics among elderly nursing home residents with dementia.


The study involved the analysis of prescription and resident files of a nationally representative sample of residents from the 2004 National Nursing Home Survey (NNHS). The study sample included an unweighted sample of 6103 elderly nursing home residents aged ≥65 years with dementia. The analysis focused on the use of six atypical antipsychotic agents and 11 typical agents. Descriptive weighted analysis was performed to examine the antipsychotic prevalence patterns in elderly nursing home residents with dementia. Multiple logistic regression analysis within the conceptual framework of Andersen’s Behavioural Model was used to examine the predisposing, enabling and need characteristics associated with use of atypical antipsychotics.


According to the 2004 NNHS, the overall prevalence of dementia among elderly nursing home residents was 52.58%. Most of the elderly with dementia were female (77%), aged ≥85 years (56%), non-Hispanic (97%) and White (88%). Antipsychotic medications were taken by 32.88% of elderly patients with dementia. More elderly residents received atypical agents (31.63%) than typical agents (1.75%). Among the predisposing characteristics, the odds of receiving atypical antipsychotics were lower for females than males. The enabling factor facility bed capacity was significantly associated with use of atypical antipsychotics. Among the need characteristics, the likelihood of receiving atypical antipsychotic agents increased with dependence in decision-making ability, indicators of depressed mood and behavioural symptoms. The likelihood of receiving atypical antipsychotic agents decreased with increasing dependence for out-of-bed mobility and increased total activities of daily living. The odds of receiving atypical antipsychotic treatment increased with the diagnosis of schizophrenia, bipolar mania and anxiety among dementia patients.


Nearly one-third of elderly nursing home residents with dementia received antipsychotic medications, mainly atypical agents. Predisposing, enabling and need factors influenced the use of atypical agents in dementia patients. These findings suggest a need to optimize use of atypical antipsychotics in elderly dementia patients in nursing homes in the light of recent efficacy and safety data.


Dementia Nursing Home Risperidone Olanzapine Atypical Antipsychotic 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



No sources of funding were used to assist in the preparation of this study. The authors have no conflicts of interest that are directly relevant to the content of this study. This research was presented in part at the 2008 Annual Conference of American Pharmacists Association at San Diego, CA, March 2008.


  1. 1.
    Agency of Healthcare Research and Quality. Efficacy and comparative effectiveness of off-label use of atypical anti-psychotics [publication no. 07-EHC003-EF]. Rockville (MD): Agency of Healthcare Research and Quality, 2007Google Scholar
  2. 2.
    Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003; 60: 1119–22PubMedCrossRefGoogle Scholar
  3. 3.
    Magaziner J, German P, Zimmerman SI, et al. The prevalence of dementia in a statewide sample of new nursing home admissions aged 65 and older: diagnosis by expert panel. Gerontologist 2000; 40: 663–72PubMedCrossRefGoogle Scholar
  4. 4.
    Eaker ED, Vierkant RA, Mickel SF. Predictors of nursing home admission and/or death in incident Alzheimer’s disease and other dementia cases compared to controls: a population-based study. J Clin Epidemiol 2002; 55:462–8PubMedCrossRefGoogle Scholar
  5. 5.
    Margallo-Lana M, Swann A, O’Brian J, et al. Prevalence and pharmacological management of behavioral and psychological symptoms amongst dementia sufferers living in care environments. Int JGeriatr Psychiatry 2001; 16: 39–44CrossRefGoogle Scholar
  6. 6.
    Gilley DW, Whalen ME, Wilson RS, et al. Hallucinations and associated factors in Alzheimer’s disease. J Neuropsychiatry Clin Neurosci 1991; 3: 371–6PubMedGoogle Scholar
  7. 7.
    Rabins PV, Mace NL, Lucas MJ. The impact of dementia on the family. JAMA 1982; 248: 333–5PubMedCrossRefGoogle Scholar
  8. 8.
    Schneider LS, Pollock VE, Lyness SA. A meta-analysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 1990; 38: 553–63PubMedGoogle Scholar
  9. 9.
    Lanctot KL, Best TS, Mittman N, et al. Efficacy and safety of neuroleptics in behavioral disorders associated with dementia. J Clin Psychiatry 1998; 59(10): 550–61PubMedCrossRefGoogle Scholar
  10. 10.
    Arana GW. An overview of side effects caused by typical antipsychotics. J Clin Psychiatry 2000; 61Suppl. 8: 5–11PubMedGoogle Scholar
  11. 11.
    Glazer WM. Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J Clin Psychiatry 2000; 61: 16–21PubMedCrossRefGoogle Scholar
  12. 12.
    Jeste DV, Lacro JP, Bailey A, et al. Incidence of tardive dyskinesia with risperidone versus haloperidol in older patients. J Am Geriatr Society 1999; 47: 716–9Google Scholar
  13. 13.
    Jeste DV, Okamoto A, Napolitano J, et al. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry 2000 Jul; 157(7): 1150–5PubMedCrossRefGoogle Scholar
  14. 14.
    Chen H, Reeves JH, Fincham JE, et al. Off-label use of antidepressant, anticonvulsant, and antipsychotic medications among Georgia Medicaid enrollees in 2001. J Clin Psychiatry 2006; 67(6): 972–82PubMedCrossRefGoogle Scholar
  15. 15.
    Glick ID, Murray SR, Vasudevan P, et al. Treatment with atypical antipsychotics: new indications and new populations. J Psychiatr Res 2001; 35(3): 187–91PubMedCrossRefGoogle Scholar
  16. 16.
    Verma SD, Davidoff DA, Kambhampati KK. Management of the agitated elderly patients in the nursing homes: the role of the atypical antipsychotics. J Clin Psychiatry 1998; 59(19): 50–5PubMedGoogle Scholar
  17. 17.
    Daniel DG. Antipsychotic treatment of psychosis and agitation in the elderly. J Clin Psychiatry 2000; 61(14): 49–51PubMedGoogle Scholar
  18. 18.
    Lee PE, Gill SS, Freedman M, et al. Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. BMJ 2004; 329: 75–8PubMedCrossRefGoogle Scholar
  19. 19.
    Deaths with Antipsychotics in elderly patients with behavioral disturbances. FDA Public Health Advisory [online]. Available from URL: [Accessed 2008 Jun 12]
  20. 20.
    FDA Public Health Advisory [online]. Available from URL: [Accessed 2009 Jul 1]
  21. 21.
    Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med 2006; 355(15): 1525–38PubMedCrossRefGoogle Scholar
  22. 22.
    Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer’s disease. Cochrane Database Syst Rev 2006; CD003476Google Scholar
  23. 23.
    Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: metaanalysis of randomized placebo-controlled trials. JAMA 2005; 294: 1934–43PubMedCrossRefGoogle Scholar
  24. 24.
    Kim H, Whall AL. Factors associated with psychotropic drug usage among nursing home residents with dementia. Nurs Res 2006; 55(4): 252–8PubMedCrossRefGoogle Scholar
  25. 25.
    Gruber-Baldini AL, Stuart B, Zuckerman IH, et al. Treatment of dementia in community dwelling and institutionalized Medicare beneficiaries. Am Geriatric Soc 2007; 55: 1508–16CrossRefGoogle Scholar
  26. 26.
    National Nursing Home Survey documentation [online]. Available from URL: [Accessed 2008 Jun 12]
  27. 27.
    Koch H, Cambell W. The collection and processing of drug information. National Ambulatory Medical Care Survey, 1980. National Center for Health Statistics. Vital Health Stat 1982; 2: 1–90Google Scholar
  28. 28.
    National Nursing Home Survey: public-use data files [online]. Available from URL: [Accessed 2008 Jun 12]
  29. 29.
    Andersen R, Newman JF. Societal and individual determinants of medical care utilization in the United States. Milbank Mem Fund Q Health Soc 1973; 51: 95–124PubMedCrossRefGoogle Scholar
  30. 30.
    Gray SL, Hanlon JT, Fillenbaum GG, et al. Predictors of nutritional supplement use by the elderly. Pharma-cotherapy 1996; 16(4): 715–20Google Scholar
  31. 31.
    Aparasu RR, Mort JR, Brandt H. Psychotropic prescription use by community-dwelling elderly in the United States. J Am Geriatr Soc 2003; 51: 671–7PubMedCrossRefGoogle Scholar
  32. 32.
    Liperoti R, Mor V, Lapane K, et al. The use of atypical antipsychotics in nursing homes. J Clin Psychiatry 2003; 64(9): 1106–12PubMedCrossRefGoogle Scholar
  33. 33.
    Liperoti R, Gambassi G, Lapane KL, et al. Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics. J Clin Psychiatry 2005; 66(9): 1090–6PubMedCrossRefGoogle Scholar
  34. 34.
    Sorensen L, Foldspang A, Gulmann N, et al. Determinants for the use of psychotropics among nursing home residents. Int J Geriatr Psychiatry 2000; 16(2): 147–54CrossRefGoogle Scholar
  35. 35.
    Hien L, Cumming R, Cameron I, et al. Atypical antipsychotic medications and risk of falls in residents of aged care facilities. J Am Geriatr Soc 2005; 53(8): 1290–5CrossRefGoogle Scholar
  36. 36.
    Frenchman BI. Atypical antipsychotics for nursing home patients a retrospective chart review. Drugs Aging 2005; 22(3): 257–64PubMedCrossRefGoogle Scholar
  37. 37.
    Rochon PA, Stukel TA, Bronskill SE, et al. Variation in nursing home antipsychotic prescribing rates. Arch Intern Med 2007; 167: 676–83PubMedCrossRefGoogle Scholar
  38. 38.
    Lindesay J, Matthews R, Jagger C. Factors associated with antipsychotic drug use in residential care: changes between 1990 and 1997. Int J Geriatr Psychiatry 2003; 18: 511–9PubMedCrossRefGoogle Scholar
  39. 39.
    Sclar DA, Robison LM, Gavrun C, et al. Hospital length of stay for children and adolescents diagnosed with depression: is primary payer an influencing factor? Gen Hosp Psychiatry 2008; 30: 73–6PubMedCrossRefGoogle Scholar
  40. 40.
    McLaughlin T, Geissler EC, Wan GJ. Comorbidities and associated treatment charges in patients with anxiety disorders. Pharmacotherapy 2003; 23(10): 1251–6PubMedCrossRefGoogle Scholar
  41. 41.
    Tour TL, Brandt NJ, Limcangco MR, et al. Impact of second-generation antipsychotics on the use of anti-parkinson agents in nursing homes and assisted-living facilities. Am J Geriatr Pharmacother 2006; 4(1): 25–35CrossRefGoogle Scholar
  42. 42.
    Continuous NHANES web tutorial: logistic regression [online]. Available from URL: [Accessed 2008 Jun 12]
  43. 43.
    Buchanan RJ, Wang S, Ju H, et al. Analyses of gender differences in profiles of nursing home residents with Alzheimer’s disease. Gend Med 2001; 1: 48–59CrossRefGoogle Scholar
  44. 44.
    Hughes CM, Lapane KL, Mor V. Influence of facility characteristics on use of antipsychotic medications in nursing homes. Med Care 2000; 38(12): 1164–73PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  • Pravin Kamble
    • 1
  • Hua Chen
    • 1
  • Jeffrey T. Sherer
    • 1
  • Rajender R. Aparasu
    • 1
  1. 1.Department of Clinical Sciences and Administration, College of PharmacyUniversity of Houston, Texas Medical CenterHoustonUSA

Personalised recommendations